Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Discover our news

Upcoming events

Dec 7-10, 2019

ASH 2019

Discover all events

a

Press contacts

Celyad

Alexandrine Hazard, Communications Associate

+32 (0)10 39 41 58

LifeSci Advisors

Sara Zelkovic

Ulysse Communication (Europe)

Bruno Arabian